Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 3, 2015, Pages 559-569

  Garg, Mayur ^a,b   Burrell, Louise M ^c   Velkoska, Elena ^c   Griggs, Karen ^c   Angus, Peter W ^c,d   Gibson, Peter R ^b   Lubel, John S ^a,b  

^a Eastern Health ^*  (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

angiotensin (1 7); angiotensin II; angiotensin converting enzyme; angiotensin converting enzyme 2; Crohn's disease; inflammatory bowel disease; Renin angiotensin system; ulcerative colitis

Indexed keywords

ALBUMIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; C REACTIVE PROTEIN; CALGRANULIN; DIPEPTIDYL CARBOXYPEPTIDASE; ANGIOTENSIN I; ANGIOTENSIN I (1-7); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENZYMATIC ASSAY; ENZYME ACTIVITY; FECES LEVEL; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; PILOT STUDY; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE COUNT; ULCERATIVE COLITIS; BLOOD; CASE CONTROL STUDY; INFLAMMATORY BOWEL DISEASE; MIDDLE AGED; UPREGULATION; YOUNG ADULT;

ADULT; AGED; ANGIOTENSIN I; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PILOT PROJECTS; RENIN-ANGIOTENSIN SYSTEM; UP-REGULATION; YOUNG ADULT;

EID: 84950312734     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320314521086     Document Type: Article

References (56)

1. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-1794.
2. AccessEconomics. The economic costs of crohn's disease and ulcerative colitis. 2007. https://www.crohnsandcolitis.com.au/content/Deloitte-Access-Economics-Report.pdf (. accessed 15/6/2012)
3. Ruiz-Ortega M, Ruperez M, Lorenzo O, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 2002; 82: S12-S22.
4. Kurikawa N, Suga M, Kuroda S, et al. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 2003; 139: 1085-1094.
5. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
6. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-33243.
7. Lubel JS, Herath CB, Burrell LM, et al. Liver disease and the renin-angiotensin system: Recent discoveries and clinical implications. J Gastroenterol Hepatol 2008; 23: 1327-1338.
8. Freeman EJ, Chisolm GM, Ferrario CM, et al. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996; 28: 104-108.
9. Benter IF, Ferrario CM, Morris M, et al. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 1995; 269: H313-H319.
10. Sampaio WO, Henrique de Castro C, Santos RA, et al. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 2007; 50: 1093-1098.
11. Zisman LS, Meixell GE, Bristow MR, et al. Angiotensin-(1-7) formation in the intact human heart: In vivo dependence on angiotensin II as substrate. Circulation 2003; 108: 1679-1681.
12. Pohl M, Kaminski H, Castrop H, et al. Intrarenal renin angiotensin system revisited: Role of megalin-dependent endocytosis along the proximal nephron. J Biol Chem 2010; 285: 41935-41946.
13. Leung PS, Chan WP, Wong TP, et al. Expression and localization of the renin-angiotensin system in the rat pancreas. J Endocrinol 1999; 160: 13-19.
14. Garg M, Angus PW, Burrell LM, et al. Review article: The pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract. Aliment Pharmacol Ther 2012; 35: 414-428.
15. Harmer D, Gilbert M, Borman R, et al. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002; 532: 107-110.
16. Hirasawa K, Sato Y, Hosoda Y, et al. Immunohistochemical localization of angiotensin II receptor and local renin-angiotensin system in human colonic mucosa. J Histochem Cytochem 2002; 50: 275-282.
17. Matsuda T, Suzuki J, Furuya K, et al. Serum angiotensin I-converting enzyme is reduced in Crohn's disease and ulcerative colitis irrespective of genotype. Am J Gastroenterol 2001; 96: 2705-2710.
18. Silverstein E, Fierst SM, Simon MR, et al. Angiotensin-converting enzyme in Crohn's disease and ulcerative colitis. Am J Clin Pathol 1981; 75: 175-178.
19. Sommer H, Schweisfurth H, Schulz M,. Serum angiotensin-I-converting enzyme and carboxypeptidase N in Crohn's disease and ulcerative colitis. Enzyme 1986; 35: 181-188.
20. Takeuchi N, Fukushima T, Sugita A, et al. [Angiotensin-converting-enzyme (ACE) in Crohn's disease]. Nippon Shokakibyo Gakkai Zasshi 1992; 89: 596-600.
21. Letizia C, D'Ambrosio C, Agostini D, et al. Serum angiotensin converting enzyme activity in Crohn's disease and ulcerative colitis. Ital J Gastroenterol 1993; 25: 23-25.
22. Studdy P, Bird R, James DG,. Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders. Lancet 1978; 2: 1331-1334.
23. Nunez-Gornes JF, Tewksbury DA,. Serum angiotensin-converting-enzyme in Crohn's disease. Am J Gastroenterol 1981; 75: 384-385.
24. Lubel JS, Herath CB, Tchongue J, et al. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci (Lond) 2009; 117: 375-386.
25. Simoes e Silva AC, Diniz JS, Pereira RM, et al. Circulating renin Angiotensin system in childhood chronic renal failure: Marked increase of Angiotensin-(1-7) in end-stage renal disease. Pediatr Res 2006; 60: 734-739.
26. Brosnihan KB, Neves LA, Anton L, et al. Enhanced expression of Ang-(1-7) during pregnancy. Braz J Med Biol Res 2004; 37: 1255-1262.
27. Zimmerman D, Burns KD,. Angiotensin-(1-7) in kidney disease: A review of the controversies. Clin Sci (Lond) 2012; 123: 333-346.
28. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 2006; 55: 749-753.
29. Chong CP, Lim WK, Velkoska E, et al. N-terminal pro-brain natriuretic peptide and angiotensin-converting enzyme-2 levels and their association with postoperative cardiac complications after emergency orthopedic surgery. Am J Cardiol 2012; 109: 1365-1373.
30. Lew RA, Warner FJ, Hanchapola I, et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 2008; 93: 685-693.
31. Herath CB, Warner FJ, Lubel JS, et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 2007; 47: 387-395.
32. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 176-180.
33. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40-46.
34. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008; 28: 1221-1229.
35. Gaya DR, Lyon TD, Duncan A, et al. Faecal calprotectin in the assessment of Crohn's disease activity. QJM 2005; 98: 435-441.
36. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162-169.
37. Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15: 1851-1858.
38. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-169.
39. Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-647.
40. Soler MJ, Wysocki J, Batlle D,. ACE2 alterations in kidney disease. Nephrol Dial Transplant 2013; 28 (11): 2687-97.
41. Soro-Paavonen A, Gordin D, Forsblom C, et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens 2012; 30: 375-383.
42. Jia HP, Look DC, Tan P, et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 2009; 297: L84-L96.
43. Cromer WE, Mathis JM, Granger DN, et al. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol 2011; 17: 578-593.
44. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012; 487: 477-481.
45. Jaszewski R, Tolia V, Ehrinpreis MN, et al. Increased colonic mucosal angiotensin I and II concentrations in Crohn's colitis. Gastroenterology 1990; 98: 1543-1548.
46. Burns WC, Velkoska E, Dean R, et al. Angiotensin II mediates epithelial-to-mesenchymal transformation in tubular cells by ANG 1-7/MAS-1-dependent pathways. Am J Physiol Renal Physiol 2010; 299 (3): F585-F593.
47. Zimpelmann J, Burns KD,. Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells. Am J Physiol Renal Physiol 2009; 296: F337-F346.
48. Katada K, Yoshida N, Suzuki T, et al. Dextran sulfate sodium-induced acute colonic inflammation in angiotensin II type 1a receptor deficient mice. Inflamm Res 2008; 57: 84-91.
49. Spencer AU, Yang H, Haxhija EQ, et al. Reduced severity of a mouse colitis model with angiotensin converting enzyme inhibition. Dig Dis Sci 2007; 52: 1060-1070.
50. Koga H, Yang H, Adler J, et al. Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: Development of a unique mode of treatment. Surgery 2008; 144: 259-268.
51. Santiago OI, Rivera E, Ferder L, et al. An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis. Regul Pept 2008; 146: 250-259.
52. Inokuchi Y, Morohashi T, Kawana I, et al. Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice. Gut 2005; 54: 349-356.
53. Wengrower D, Zanninelli G, Pappo O, et al. Prevention of fibrosis in experimental colitis by captopril: The role of tgf-beta1. Inflamm Bowel Dis 2004; 10: 536-545.
54. Chappell MC, Pirro NT, Sykes A, et al. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 1998; 31: 362-367.
55. Ferrario CM, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 2005; 68: 2189-2196.
56. Kasper SO, Basso N, Kurnjek ML, et al. Divergent regulation of circulating and intrarenal renin-angiotensin systems in response to long-term blockade. Am J Nephrol 2005; 25: 335-341.